Last reviewed: July 3, 2026
Last updated: July 3, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) was originally designed for type 2 diabetes, but clinical evidence now supports its use for weight management in eligible patients. Understanding who qualifies for this treatment requires knowing both the formal medical criteria and the practical barriers that prevent many candidates from accessing it.
Medical Eligibility Requirements for Semaglutide Weight Loss
Semaglutide eligibility for weight management centers on body composition and metabolic health markers. Candidates typically have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or heart disease. Some patients with lower BMI but significant metabolic concerns also qualify, depending on individual health assessment.
Age matters in eligibility screening. Adults aged 18 and older are candidates for semaglutide therapy. Pregnancy and breastfeeding are contraindications, as the medication can affect fetal development. A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 also excludes candidates from this treatment class.
Kidney and liver function testing typically precedes semaglutide initiation. Patients with severe kidney disease or certain liver conditions may require dose adjustment or alternative approaches. PlexusDx reviews current medications and medical history to identify safe candidacy before compounding begins.
How BMI and Weight-Related Conditions Determine Qualification
The FDA recognizes weight loss eligibility at a BMI of 30 kg/m² or higher in adults without other health conditions. This threshold captures roughly 40 million American adults. However, qualification also applies to individuals with a BMI between 27 and 29.9 who have established weight-related conditions like hypertension, type 2 diabetes, or cardiovascular disease.
Weight-related conditions that support qualification include obstructive sleep apnea, osteoarthritis, polycystic ovary syndrome, and fatty liver disease. These conditions create metabolic stress that semaglutide can help reduce. Documentation of at least one such condition, combined with a BMI above 27, opens access to treatment.
Waist circumference and body composition offer additional context beyond BMI alone. Some patients qualify based on central obesity patterns even if their overall BMI falls in borderline ranges. PlexusDx assessment includes discussion of these broader metabolic factors to determine true clinical need.
Access Barriers and Why Compounded Semaglutide Expands Eligibility
Brand-name Ozempic carries significant cost and insurance barriers that prevent eligible patients from accessing treatment. Many insurance plans require prior authorization, demand proof of diabetes or specific conditions, or impose high copayments. Patients without insurance face even steeper obstacles, with retail prices often exceeding $900 monthly.
PlexusDx removes these barriers by offering compounded semaglutide injection starting at $149 monthly through licensed 503A compounding pharmacies. No insurance is required, no membership fees apply, and HSA or FSA funds are accepted. This pricing structure means that medically eligible patients can afford treatment regardless of employment status or insurance coverage.
Compounded semaglutide meets the same quality and potency standards as branded versions while remaining accessible to underserved populations. The medication comes from licensed compounding facilities, not mass-production factories, allowing PlexusDx to serve all 50 states and maintain competitive pricing without compromising clinical standards.
Genetic Testing and Personalized Eligibility Assessment
Beyond standard eligibility screening, individual genetic factors influence semaglutide response rates and optimal compound selection. PlexusDx offers the Precision Peptide Genetic Test, which identifies variants in GLP1R, GIPR, FTO, and MC4R genes that shape appetite regulation and weight loss potential. This test reveals whether patients are likely to respond robustly or moderately to GLP-1 therapy.
The Precision Peptide Genetic Test ($99 add-on after first treatment month) maps 14 metabolic pathways and 150+ genetic insights specific to peptide responsiveness. Results help PlexusDx determine whether semaglutide injection, oral formulations, tirzepatide, or combination protocols best match individual biology. Patients with genetic predispositions toward GLP-1 sensitivity may see faster results, while others benefit from dual-compound approaches.
Genetic eligibility assessment ensures that treatment selection aligns with metabolic individual differences rather than one-size-fits-all protocols. Patients with FTO rs9939609 variants linked to appetite dysregulation, for example, may experience enhanced benefit from semaglutide compared to other interventions.
Step-by-Step Qualification and Enrollment at PlexusDx
PlexusDx qualification begins with a detailed health questionnaire covering weight history, medical conditions, medications, and lifestyle factors. This initial screening identifies contraindications and establishes baseline eligibility. Patients provide their BMI, blood pressure readings, and relevant lab results if available.
After eligibility confirmation, PlexusDx connects patients with a licensed clinician who reviews the complete medical profile. This telehealth consultation ensures semaglutide is appropriate and safe for the individual. The clinician addresses questions, discusses expected outcomes, and explains the dose-adjustment timeline—reminding patients that "your dose may need to go up; your price won't."
Once approved, PlexusDx submits the prescription to a licensed 503A compounding pharmacy for preparation. Treatment begins with a starter dose, then titrates upward based on tolerance and response. Patients maintain ongoing contact with the PlexusDx clinical team throughout their journey.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need to have type 2 diabetes to qualify for semaglutide weight loss?
No. While semaglutide was initially approved for diabetes, weight loss eligibility applies to non-diabetic adults with a BMI of 30 or higher, or BMI 27+ with weight-related conditions like hypertension or heart disease. PlexusDx evaluates each patient's full medical picture to confirm qualification.
What is the minimum BMI required to qualify for semaglutide?
A BMI of 30 or higher qualifies most adults. Those with a BMI between 27 and 29.9 can also qualify if they have documented weight-related conditions such as type 2 diabetes, hypertension, obstructive sleep apnea, or cardiovascular disease. PlexusDx reviews your specific health profile during the qualification process.
Can I afford semaglutide if I don't have insurance?
Yes. PlexusDx compounded semaglutide injection starts at $149 monthly with no insurance required and no membership fees. HSA and FSA accounts are accepted, making treatment accessible to uninsured and underinsured patients alike.
What conditions make someone ineligible for semaglutide?
Personal or family history of medullary thyroid cancer and multiple endocrine neoplasia syndrome type 2 are absolute contraindications. Pregnancy, breastfeeding, and severe kidney or liver disease also prevent qualification. PlexusDx screens for these conditions during the initial consultation.
How does the Precision Peptide Genetic Test affect my eligibility?
The genetic test does not determine eligibility but rather informs treatment optimization. It identifies variants in GLP1R, GIPR, FTO, and MC4R genes that predict your likely response to semaglutide or alternative compounds. PlexusDx uses these insights to personalize your protocol for maximum results.
How long does the PlexusDx qualification process take?
Initial screening through questionnaire typically takes 24 hours. Your clinician consultation and prescription processing follows within 2-3 business days. Once approved, your compounded medication ships promptly so you can begin treatment within one week of enrollment.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Is Insomnia a Side Effect of Ozempic? Understanding the Connection
What to Eat After Your Ozempic Injection to Minimize Nausea